Tiempo real estimado
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
3,4 USD | +1,80 % | -8,33 % | +98,80 % |
Resumen de negocios
Número de empleados: 28
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Joel Lewis
CEO | Chief Executive Officer | 54 | 01/12/17 |
Jack Callicutt
DFI | Director of Finance/CFO | 56 | 01/07/13 |
Ezra R. lowe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Pol Boudes
CTO | Chief Tech/Sci/R&D Officer | 67 | 02/03/20 |
Harold Shlevin
BRD | Director/Board Member | 75 | 01/10/12 |
Susan Thornton
LAW | General Counsel | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Kevin Freeman
BRD | Director/Board Member | 62 | 01/05/11 |
Benjamin Carson
BRD | Director/Board Member | 73 | 07/12 |
Gil Omenn
BRD | Director/Board Member | 83 | 23/09/14 |
Gilbert Amelio
BRD | Director/Board Member | 81 | 12/02/09 |
Harold Shlevin
BRD | Director/Board Member | 75 | 01/10/12 |
Dick Uihlein
CHM | Chairman | 79 | 14/12/17 |
Marc Rubin
BRD | Director/Board Member | 69 | 12/10/11 |
Kary Eldred
BRD | Director/Board Member | 50 | 01/01/18 |
Richard Zordani
BRD | Director/Board Member | 52 | 01/09/20 |
Elissa Schwartz
BRD | Director/Board Member | 54 | 01/09/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 1 235 000 | 0 | 0 | 67,53 % |
Acción B | 1 | 61 903 672 | 42 636 943 ( 68,88 %) | 0 | |
Acción C | 0 | 176 | 0 | 0 |
Información de la empresa
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard Suite 240
30071, Norcross
+(678) 620-3186
http://www.galectintherapeutics.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+98,80 % | 207 M | |
+21,76 % | 47,9 mil M | |
+46,62 % | 41,42 mil M | |
-2,18 % | 40,7 mil M | |
-6,20 % | 28,92 mil M | |
+10,19 % | 25,55 mil M | |
-20,87 % | 19,27 mil M | |
-0,32 % | 12,15 mil M | |
+31,04 % | 12,14 mil M | |
-0,47 % | 11,99 mil M |
- Bolsa de valores
- Acciones
- Acción GALT
- Empresa Galectin Therapeutics Inc.